Norway – Healthcare, Regulatory and Reimbursement Landscape

GlobalData, the industry analysis specialist, has released its latest report, "Norway – Healthcare, Regulatory and Reimbursement Landscape". The report is an essential source of information on analysis of healthcare, regulatory, and reimbursement landscape in Norway. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

The Norway pharmaceutical market was worth $3.29 in 2013, which decreased to $3.26B in 2019 at a negative CAGR of 0.13%. The market value is expected to decrease further to $3.23B by 2025. Norway is a well-developed healthcare market in Northern Europe with the patient-centered approach towards care and treatment, data-driven innovation, and universal health coverage. In January 2016, the Norwegian Directorate of eHealth (NDE) was established to implement several national eHealth policies and encourage the adoption of digital health solutions.

Norway’s robust healthcare system, increasing elderly population, increased prevalence of chronic diseases, and growing pharmaceutical consumption are attributed to the growth of the pharmaceutical market.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Norway, and includes:

An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

Profiles and SWOT analyses of the major players in the pharmaceutical market: Pfizer, Novartis, Sanofi, GSK, and Navamedic

Profiles and SWOT analyses of the major players in the medical device market: Abbott, Medtronic, Roche, Alcon, and Photocure

An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in the healthcare market, healthtech landscape, reimbursement, and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices

Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure, and healthcare expenditure

An overview of the opportunities for and challenges to growth in the Norway healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to:

Develop business strategies by understanding the trends shaping and driving Norway’s healthcare market

Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact Norway’s healthcare market in the future

Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

Table of Contents

1. Table of Contents

1.1List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights: Facts about the Norway Healthcare Market

2.3 Key Highlights: Healthcare Startups in Norway

2.4 Key Events: Norway Healthcare Timeline, 2015-2021

2.5 Key Events: Norway Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2019-2020

2.7 Key Events: Top Completed Deals by Value, 2019-2020

2.8 Country Profile, Norway, 2020

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Norway

3.5 Pharmaceutical Market – Market Segments

3.6 Major Therapeutic Areas, Norway

3.7 COVID-19 Epidemiology, Norway

3.8 COVID-19 Impact and Developments in the Healthcare Market, Norway

3.9 COVID-19 Clinical Trials Landscape, Norway

3.10 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Norway, 2019-2021

6.2 Deal Analysis: Medical Device Market, Norway, 2019-2021

7. HealthTech Landscape

7.1HealthTech Deals Landscape, Norway

7.2 HealthTech Ecosystem, Norway

7.3 Adoption of Technology in Healthcare, Norway

7.4 Key HealthTech Deals, Norway

7.5 Government-Sponsored Schemes Promoting Startups, Norway

7.6 Regulatory Scenario Covering Use of Technology in Healthcare, Norway

7.7 HealthTech Landscape: Benefits and Risks, Norway

8. Market Access

8.1 Overview of Healthcare System, Norway

8.2 Reimbursement Process, Norway

8.3 Overview of Insurance Providers, Norway

8.4 Healthcare Spending and Medicine Price Index, Norway

8.5 Pricing Policies, Norway

8.6 Regulatory Landscape, Norway

8.6.1 Marketing Authorization for Pharmaceutical Products, EU

8.6.2 Marketing Authorization for Pharmaceutical Products, Norway

8.6.3 Market Authorization for Medical Devices, Norway

8.6.4 Imports, Norway

8.6.5 Intellectual Property Rights, Patent, Norway

8.6.6 Intellectual Property Rights, European Patent, Norway

8.6.7 Intellectual Property Rights, Trademarks, Norway

8.6.8 Clinical Trial Regulation Process, Norway

8.6.9 Pharmaceutical Clinical Trials Landscape, Norway

8.6.10 Medical Devices Clinical Trials Landscape, Norway

8.6.11 Pharmaceutical Advertisement Regulations, Norway

8.6.12 Pharmacy Regulations, Norway

8.6.13 Labeling and Packaging Regulations, Norway

9. Country Healthcare Landscape

9.1 Healthcare Policy Highlights

9.2 Healthcare Facilities, Norway

9.3 Healthcare Parameters, Norway

9.4 Life Expectancy and Immunization Rate, Norway

9.5 Environmental Health, Norway

9.6 Healthcare Personnel, Norway

9.7 Disease Burden, Norway

9.8 Healthcare Expenditure, Norway

9.9 Healthcare Spending Components and Pharmaceutical Spending, Norway

10 Trade Associations, Norway

11 Trade Fairs, Norway

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

List of Tables

Table 1: Pharmaceutical Market, Norway, Sales of Patented Drug Products by Major Therapeutic Class ($M), 2019

Table 2: COVID-19 Indicators (Number of Cases), Global and Norway, 2021

Table 3: COVID-19-Related Travel Restrictions, Norway, 2020-2021

Table 4: COVID-19 In Vitro Diagnostics Products, Norway, 2021

Table 5: Medical Device Market, Norway, Major Segments ($M), 2020

Table 6: Orthopedic Devices Market, Norway, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 7: Cardiovascular Devices Market, Norway, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 8: General Surgery Market, Norway, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 9: Wound Care Management Market, Norway, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 10: In Vitro Diagnostics Market, Norway, Revenue ($M) and Market Share (%) of Major Companies, 2018

Table 11:Reimbursement Categories and Rates, Norway, 2020

Table 12: Reimbursement Prescription Schemes, Norway, 2020

Table 13: National Insurance Contribution Rates, Norway, 2020

Table 14: Pricing Procedures, Norway, 2020

Table 15: Marketing Authorization Application Fee (National Procedure) for Human Use , Norway, 2021

Table 16: Types of Import Authorizations for Clinical Studies, Norway, 2020

Table 17: Patent Fees, Norway, 2020

Table 18: Trademark Fees, Norway, 2020

Table 19: Clinical Trial Regulation, Norway, 2020

Table 20: Advertising Regulations, Norway, 2020

Table 21: Labelling And Package Leaflet Regulations, Norway, 2020

Table 22: Nordic Package Regulation, 2020

List of Figures

Figure 1: Pharmaceutical Market, Norway, Revenue ($B), 2013-2019

Figure 2: Medical Device Market, Norway, Revenue ($B), 2015-2020

Figure 3: Healthcare Startups in Norway, 2020

Figure 4: Number of Deals (2019-2020)

Figure 5: 2019-2020 Deal Overview by Region

Figure 6: Country Profile, Norway, 2020

Figure 7: Pharmaceutical Market, Norway, Revenue ($B), 2013-2019

Figure 8: Pharmaceutical Market, Norway, Revenue Forecast ($B), 2020-2025

Figure 9: Pharmaceutical Exports ($B), Norway, 2013-2020

Figure 10: Top Export Partners, Norway, 2020

Figure 11: Pharmaceutical Imports ($B), Norway, 2013-2020

Figure 12: Top Import Partners, Norway, 2020

Figure 13: Pharmaceutical Supply Channel, Norway, 2020

Figure 14: Generic Drugs Usage (% Share by Volume), Norway, 2012-2018

Figure 15: Generic Drugs Usage (% Share by Value), Norway, 2012-2018

Figure 16: OTC Market, Norway, Revenue ($B), 2012-2020

Figure 17: OTC Medicines Market, Major Categories ($M), Norway, 2020

Figure 18: OTC Medicines Market, Major Distribution Channels ($M), Norway, 2020

Figure 19: Pharmaceutical Market, Norway, Sales of Patented Drug Products by Major Therapeutic Class, 2019

Figure 20: COVID-19 (Cases), Norway, 2020-2021

Figure 21: COVID-19 (Deaths), Norway, 2020-2021

Figure 22: COVID-19 Fiscal Stimulus Timeline, Norway, 2020-2021

Figure 23: Cumulative Number of COVID-19 Vaccine Doses Administered, Norway, 2021

Figure 24: COVID-19 Clinical Trials Count By Trial Status, Norway, 2020-2021

Figure 25: COVID-19 Clinical Trials Count By Phase, Norway, 2020-2021

Figure 26: Top Five COVID-19 Clinical Trials Sponsors By Count, Norway, 2020-2021

Figure 27: Medical Device Market, Norway, Revenue ($B), 2015-2020

Figure 28: Medical Device Market, Norway, Revenue Forecast ($B), 2021-2025

Figure 29: Medical Device Market, Norway, Major Segments (%), 2020

Figure 30: General Surgery Market, Norway, Revenue ($M), 2017-2025

Figure 31: General Surgery Market, Norway, Market Share of Major Players (%), 2019

Figure 32: Orthopedic Devices Market, Norway, Revenue ($M), 2017-2025

Figure 33: Orthopedic Devices Market, Norway, Market Share of Major Players (%), 2019

Figure 34: Wound Care Management Market, Norway, Revenue ($M), 2017-2025

Figure 35: Wound Care Management Market, Norway, Market Share of Major Players (%), 2019

Figure 36: Cardiovascular Devices Market, Norway, Revenue ($M), 2017-2025

Figure 37: Cardiovascular Devices Market, Norway, Market Share of Major Players (%), 2019

Figure 38: In Vitro Diagnostics Market, Norway, Revenue ($M), 2017-2025

Figure 39: In Vitro Diagnostics Market, Norway, Market Share of Major Players (%), 2018

Figure 40: Diagnostics Market, Norway, Revenue ($M), 2015-2020

Figure 41: Diagnostics Market, Norway, Revenue ($M), 2021-2025

Figure 42: Medical Devices Market, Revenue ($B) of Major Companies, Norway, 2019

Figure 43: Deal Value and Deal Count, Pharmaceutical Market, Norway, 2019-2021

Figure 44: Deal Value and Deal Count Subtypes, Pharmaceutical Market, Norway, 2019-2021

Figure 45: Deal Value and Deal Count, Quarterly, Pharmaceutical Market, Norway, 2019-2021

Figure 46: Top Therapy Areas by Deal Value, Pharmaceutical Market, Norway, 2019-2021

Figure 47: Top Therapy Areas by Deal Count, Pharmaceutical Market, Norway, 2019-2021

Figure 48: Mergers and Acquisitions Deals by Quarter, Pharmaceutical Market, Norway, 2019-2021 (by Value and by Number)

Figure 49: Venture Financing Deals by Quarter, Pharmaceutical Market, Norway, 2019-2021 (by Value and by Number)

Figure 50: Deal Value and Deal Count, Medical Devices Market, Norway, 2019-2021

Figure 51: Deal Value and Deal Count, Quarterly, Medical Devices Market, Norway, 2019-2021

Figure 52: Deal Value and Deal Count Subtypes, Medical Devices Market, Norway, 2019-2021

Figure 53: Top Equipment Sectors by Deal Value, Medical Devices Market, Norway, 2019-2021

Figure 54: Top Equipment Sectors by Deal Count, Medical Devices Market, Norway, 2019-2021

Figure 55: Venture Financing Deals by Equipment Sector, Medical Devices Market, Norway, 2019-2021 (by Value and by Number)

Figure 56: Deal Value ($M), HealthTech, Norway, 2019-2021

Figure 57: Deal Count ($M), HealthTech, Norway, 2019-2021

Figure 58: HealthTech Ecosystem, 2020

Figure 59: Organization of the Health System, Norway, 2020

Figure 60: Decision Making Process, Norway, 2020

Figure 61: OOP Expenditure (% of Total Expenditure on Health), Norway, 2012-2019

Figure 62: Annual Rate of Change (%), Health Price Index, Norway, 2013-2019

Figure 63: Norwegian Medicines Agency, Organization Chart, 2020

Figure 64: Marketing Authorization for Pharmaceutical Products, EU, 2020

Figure 65: National Procedure, Norway, 2020

Figure 66: Centralized Procedure, Norway, 2020

Figure 67: Decentralized Procedure, Norway, 2020

Figure 68: Mutual Recognition Procedure, Norway, 2020

Figure 69: Conformity Assessment of Class I Medical Devices, EU, 2020

Figure 70: Conformity Assessment of Class IIa Medical Devices, EU, 2020

Figure 71: Conformity Assessment of Class IIb Medical Devices, EU, 2020

Figure 72: Conformity Assessment of Class III Medical Devices, EU, 2020

Figure 73: European Patent Approval Process, EU, 2020

Figure 74: Pharmaceutical Clinical Trials Count By Trial Status, Norway, 2020-2021

Figure 75: Pharmaceutical Clinical Trials Count By Indication, Norway, 2020-2021

Figure 76: Pharmaceutical Clinical Trials Count By Phase, Norway, 2020-2021

Figure 77: Top Five Pharmaceutical Clinical Trials Sponsors By Count, Norway, 2020-2021

Figure 78: Medical Devices Clinical Trials Count by Trial Status, Norway, 2020-2021

Figure 79: Medical Devices Clinical Trials Count by Indication, Norway, 2020-2021

Figure 80: Medical Devices Clinical Trials Count by Category, Norway, 2020-2021

Figure 81: Top Five Medical Devices Clinical Trial Sponsors by Count, Norway , 2020-2021

Figure 82: Number of Hospitals, Norway, 2013-2020

Figure 83: Number of Diagnostic Equipment, Norway, 2015-2020

Figure 84: Number of Hospital Beds (per 1,000 Population), Norway, 2013-2020

Figure 85: Number of Acute Care Beds (per 1,000 Population), Norway, 2013-2020

Figure 86: Number of Psychiatric Care Beds (per 1,000 Population), Norway, 2013-2020

Figure 87: Life Expectancy at Birth (Years), Norway, 2013-2020

Figure 88: Immunization Rate (%), Norway, 2012-2019

Figure 89: PM2.5 (µg per m3), Norway, 2013-2020

Figure 90: CO2 Emissions (Million Tons), Norway, 2013-2020

Figure 91: Physicians (per 1,000 Population), Norway, 2013-2020

Figure 92: Dentists (per 1,000 Population), Norway, 2013-2020

Figure 93: Pharmacists (per 1,000 Population), Norway, 2013-2020

Figure 94: Nurses (per 1,000 Population), Norway, 2013-2020

Figure 95: Major Causes of Mortality (per 1,000 population), Norway, 2019

Figure 96: Major Causes of Male Mortality (per 1,000 population), Norway, 2019

Figure 97: Major Causes of Female Mortality (Per 1,000 Population), Norway, 2019

Figure 98: Disability-Adjusted Life Years by Major Disease (Per 1,000 Population), Norway, 2019

Figure 99: Healthcare Expenditure as Percentage of GDP (%), Norway, 2013-2020

Figure 100: Public-Private Share (%), Norway, 2013-2020

Figure 101: Healthcare Expenditure Components by Function (% of Total Health Expenditure), Norway, 2019

Figure 102: Pharmaceutical Spending ($ Per Capita), Norway, 2011-2019

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports